Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
about
Clinical advances in molecular biomarkers for cancer diagnosis and therapyBurden of illness for metastatic melanoma in Canada, 2011-2013Evaluating biomarkers in melanoma.Immune based therapy for melanomaTargeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results.Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts.Metastatic breast disease from cutaneous malignant melanomaFAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPARγ/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells.Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.New combinations and immunotherapies for melanoma: latest evidence and clinical utility.Melanoma biomolecules: independently identified but functionally intertwined.Prospects for MEK inhibitors for treating cancer.Dendritic cell-based vaccines: clinical applications in breast cancer.New RAF kinase inhibitors in cancer therapy.Vemurafenib for the treatment of BRAF mutant metastatic melanoma.BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.An uncommon presentation of metastatic melanoma: a case report.Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Malignant Melanoma.Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
P2860
Q27027560-573904FC-197C-4474-918A-62BB6DD69507Q28354125-85D8EE31-1632-4886-A2AA-3FF116750B0DQ35005677-BFD7019E-7C95-402F-AC34-6A40CDA50D0EQ36876757-32D98F54-8EA6-44C1-9A3B-476B1BC160D2Q37123297-0BF4FDFB-236F-44DC-B98A-2519950BFC55Q37418121-F56392CA-F5E0-4588-8519-A787344A7499Q37533430-F80DFE04-EF62-4707-914E-DD4B575ABEEFQ37706722-8351B6C2-0758-4323-A8E9-0BC3C8859FB8Q38124821-7EC128EF-A156-4A60-8B1F-F62DDC7111A9Q38133560-9E82796A-8D50-448F-8F3B-DA42F2472D1DQ38143977-A72E22C0-0706-476C-B219-74BA3210FA59Q38193520-2A019129-D8C9-4136-91BB-704306DB436FQ38206821-A3C1B9AA-728F-4168-A9E7-D30AE258A6A4Q38207082-9653B5B2-0802-4B9B-A399-E475EC209D3DQ38357122-7A718F7D-CC28-4D5F-B341-43A99C74D5EFQ38498046-7A2AA42F-276C-418C-8327-E8554786CEBAQ41888760-65E51C14-1C3E-47A6-8A06-8FBF8B33A9D2Q48128794-BFC9416E-F895-46F6-93EF-CF76D03B39BBQ54432652-718BDBB9-6FDB-4DD2-86D9-F2E5567CAE62Q58700213-85D3DBCB-AF20-42DD-B354-8DF8F8D1D9FC
P2860
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
@en
type
label
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
@en
prefLabel
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
@en
P2093
P2860
P356
P1476
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.
@en
P2093
James Larkin
Muhammad Khattak
Rosalie Fisher
Samra Turajlic
P2860
P304
P356
10.1177/1758834012466280
P577
2013-03-01T00:00:00Z